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Abstract: Short but accurate cognitive screening instruments are required in busy clinical practice.
Although widely-used, the diagnostic accuracy of the standardised Mini-Mental State Examination
(SMMSE) in different dementia subtypes remains poorly characterised. We compared the SMMSE
to the Quick Mild Cognitive Impairment (Qmci) screen in patients (n = 3020) pooled from three
memory clinic databases in Canada including those with mild cognitive impairment (MCI) and
Alzheimer’s, vascular, mixed, frontotemporal, Lewy Body and Parkinson’s dementia, with and
without co-morbid depression. Caregivers (n = 875) without cognitive symptoms were included as
normal controls. The median age of patients was 77 (Interquartile = ±9) years. Both instruments
accurately differentiated cognitive impairment (MCI or dementia) from controls. The SMMSE most
accurately differentiated Alzheimer’s (AUC 0.94) and Lewy Body dementia (AUC 0.94) and least
accurately identified MCI (AUC 0.73), vascular (AUC 0.74), and Parkinson’s dementia (AUC 0.81).
The Qmci had statistically similar or greater accuracy in distinguishing all dementia subtypes but
particularly MCI (AUC 0.85). Co-morbid depression affected accuracy in those with MCI. The SMMSE
and Qmci have good-excellent accuracy in established dementia. The SMMSE is less suitable in
MCI, vascular and Parkinson’s dementia, where alternatives including the Qmci screen may be used.
The influence of co-morbid depression on scores merits further investigation.
Keywords: dementia; mild cognitive impairment; screening; accuracy; standardised mini-mental
state examination; quick mild cognitive impairment screen
1. Introduction
Although short cognitive screening instruments (CSIs) such as the Mini-Mental State Examination
(MMSE) [1] and its standardised version, the SMMSE [2,3] are widely used in clinical practice and
research studies, their accuracy and hence suitability for use in detecting different dementia subtypes
is poorly characterised [4]. Numerous studies including recent systematic reviews show that the
MMSE has poor accuracy and that an alternative instrument should be used to identify those with
mild cognitive impairment (MCI) [5], a prodromal state characterised by cognitive deficits without loss
of social or occupation function and before the onset of dementia [6]. Other instruments such as the
Memory Alteration Test [7], the Quick Mild Cognitive Impairment (Qmci) screen [8] and Montreal
Cognitive Assessment (MoCA) [9] are recommended as alternatives [5,10]. The MMSE has a “floor”
effect such that a score of zero does not always support dementia and a “low ceiling” effect such that a
normal score does not always mean normal cognition [11]. It is also influenced by age and education
meaning that it is poorly sensitive when used among older and less educated adults [12,13]. It also has
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poor reliability, which led to the development of the SMMSE. Despite these issues, the MMSE remains
the most widely used CSI in clinical practice [14].
Given that the MMSE and SMMSE cover a limited number of cognitive domains [2,3],
their diagnostic accuracy in different types of dementia is unclear. The SMMSE lacks a subtest
measuring executive function, which suggests that it is less useful in those with Parkinson’s disease
cognitive impairment [15] and is overly weighted towards language skills, making it less useful in
frontotemporal dementia [16]. Compared with other short CSIs such as the MoCA, the MMSE has poor
accuracy in detecting vascular cognitive impairment, which is often characterised by impaired attention,
executive and visuospatial dysfunction, all poorly assessed with the MMSE subtests [17]. Similarly,
the pentagon task may lack accuracy in post-stroke, frontotemporal and subcortical dementias [18].
Low mood and depression may also impact on cognition and may precede onset of cognitive
decline, affecting executive function, memory, and attention [19,20]. While evidence suggests that
depression in MCI is associated with disease progression, the effects of depression on cognitive
screening are poorly characterised [21]. Limited data suggests that mood may negatively influence
MMSE scores, underestimating true performance [22]. The extent to which depression affects the
results of the MMSE and other CSIs and their subtests is however, poorly understood and the extent to
which different dementia subtype scores are influenced by the presence of comorbid depression is
not known.
Although several studies have compared the diagnostic accuracy of the newer and shorter Qmci
screen and shown it is better able to differentiate MCI from mild dementia and normal cognition than
the SMMSE [8,13], to date, this has only been examined in those with Alzheimer’s and vascular type
dementia. The objective of this study is therefore to explore the performance (diagnostic accuracy) of
these instruments across a broad range of different dementia subtypes, and in patients with MCI and
those with and without depression. More broadly, this also serves to investigate the extent to which
CSI’s perform differently in these settings.
2. Methods
2.1. Data Collection
This study compared the SMMSE and the Qmci screen in patients (n = 3020) obtained from three
geriatric and memory clinics in Canada over the decade between 1999 and 2010. Data were collected and
analysed retrospectively from two clinic databases and a randomised controlled clinical trial dataset:
The Geriatric Assessment Tool (GAT) [23], the Qmci screen original validation [8], and the Doxycycline
and Rifampicin for Alzheimer’s Disease (DARAD) Trial databases [24]. Recruitment processes from all
three studies have been published previously [8,23,24]. In summary, the GAT is a customised software
application that automates clinicians’ outpatient reviews [23]. These data were collected in outpatient
geriatric and memory clinics in two university hospitals in Ontario, Canada between 1999 and 2010.
It contains approximately 8000 individual assessments from 1749 people aged 41–104 years. The Qmci
screen validation database includes patients referred for assessment of cognition aged ≥55 years
and recruited from four memory clinics in Ontario Canada [8]. The DARAD was a multi-centre,
blinded, randomised trial conducted between 2006 and 2010, comparing the effect of rifampicin
and doxycycline to placebo on the progression of AD [24]. The DARAD database includes patients
≥50 years with mild to moderate AD recruited from 14 centres across Canada. All three studies were
led by the same principle investigator (D.W.M) and each participant underwent similar comprehensive
work-up including laboratory investigations, neuropsychological assessment and neuroimaging where
appropriate [23,24]. Ethical approval was obtained in advance for all three studies and participants
provided informed written consent.
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2.2. Participants
Participants were included in this analysis if both their SMMSE and Qmci screen scores
were available. Participant selection is presented in Figure 1. MCI was diagnosed in patients
presenting with subjective and objective memory loss, without loss of function. This was
consistent with Petersen’s criteria, where patients present with subjective memory complaints,
objective abnormal memory function but preservation of activities of daily living and have no
evidence of dementia [25]. Dementia was diagnosed using the Diagnostic and Statistical Manual of
Mental Disorders (4th-edition) [26]. Mood was screened using the geriatric depression scale-short
form with scores ≥5 assessed clinically for depression [27]. All participants were English literate.
Those with MCI, predominantly amnestic type (aMCI), and patients with Alzheimer’s disease (AD),
vascular dementia (VaD), frontotemporal dementia (FTD), Lewy body dementia (LBD) and Parkinson’s
disease dementia (PDD), meeting established clinical criteria, with and without a history of comorbid
depression, were included. Patients without cognitive impairment and with depression as the primary
symptom were excluded. Persons attending with patients without memory loss (mainly caregivers)
were recruited by convenience sampling as normal controls (n = 875).
2.3. Outcome Measures
The SMMSE is a standardised form of the MMSE developed to improve inter-rater reliability and
reduced administration time by using explicit administration and scoring guidelines [2,3]. Scored out of
30 points, a score of 25/30 or more suggests that the individual may have normal cognition. Below this,
scores can indicate mild (21–24 points), moderate (10–20 points) and severe cognitive impairment
(≤9 points), though a cut-off of <24/30 optimises sensitivity [2,3]. It covers several cognitive domains
including orientation, registration, delayed (verbal) recall, attention (concentration and calculation),
language (including writing, reading and naming), command following, and visuospatial (construction)
subtests [2,3]. The Qmci screen is a more recently developed short CSI, designed to separate MCI from
mild dementia [8]. Scored from 100 points it incorporates six subtests across five cognitive domains
including orientation, working memory, sematic memory (verbal fluency-categories), visuo-spatial
(clock drawing) and two tests of episodic memory: Delayed recall and logical memory (immediate
verbal recall of short a story) [28]. It has an optimal cut-off score for cognitive impairment of
<62/100 [13,29]. It has been validated against the MoCA and different neuropsychological tests and
is published in multiple languages [30–34]. While data on total scores were available for both CSIs,
data on subtests were only available for the Qmci screen as these were not collected as part of the
DARAD trial [24].
2.4. Analysis
Data were analysed using SPSS 24.0. Data from the three data sets (original Qmci screen validation
database, GAT and DARAD datasets) were pooled and analysed using simple descriptive statistics.
Data were non-normally distributed and were analysed with non-parametric tests. The Mann–Whitney
U test was used to compare distributions between variables. Receiver operating characteristic (ROC)
curve analysis was used to determine diagnostic accuracy from the area under the curve (AUC).
AUC scores range from 0.5–1.0; 0.5 equates to chance alone and 1.0 perfect predictive accuracy.
Scores from 0.50–0.59 indicate no or very poor accuracy, 0.60–0.69 poor, 0.70–0.79 fair, 0.80–0.89 good
and 0.90–1.0 excellent to perfect accuracy [35]. All AUC values are presented with 95% confidence
intervals (CI) and where specified were compared using the DeLong method [36]. Optimal cut-off
points were calculated using Youden’s Index.
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Figure 1. Flow chart presenting the recruitment of participants pooled from three data sets: The 
Geriatric Assessment Tool (GAT), Quick Mild Cognitive Impairment (Qmci) Screen and Doxycycline 
and Rifampicin for Alzheimer’s Disease (DARAD) trial databases; it includes the number of controls, 
those with mild cognitive impairment (MCI) and specific dementia subtypes: Alzheimer’s disease 
(AD), vascular dementia (VaD), mixed dementia, frontotemporal dementia (FTD), Parkinson’s 
disease dementia (PDD) and Lewy body dementia (LBD) subtypes. 
3. Results. 
In all, 3020 patients were available for analysis. A further 875 normal controls were included. 
The majority of participants had dementia (n = 2,160) of which AD was the most common subtype (n 
= 1483), followed by mixed (AD-VaD) (n = 400) and VaD (n = 130). The median age of patients 
presenting with cognitive symptoms (MCI/dementia) was 77 years, interquartile range (IQR) ±9 
compared to a median age of 69 (±14) years for normal controls, p < 0.001. In all, 51% of patients were 
male compared to 43% of controls, p < 0.001. Patients had completed a median of 12 (±5) years in 
education, similar to controls (13±4), albeit statistically significantly lower, p < 0.001. The median 
SMMSE scores were 23/30 (+/−8) for dementia, 28/30 (±4) for MCI and 29/30 (±2) for controls. Median 
Qmci screen scores were 38/100 (±26) for dementia, 56/100 (±20) for MCI and 74/100 (±15) for controls. 
Differences in gender were seen between diagnosis with the percentage of males ranging from as 
high as 73% in those with VaD to as low as 41% in those with dementia and comorbid depression. 
Characteristics of participants including patients and controls are presented in Table 1.
Figure 1. Flow chart presenting the recruitment of participants pooled from three data sets: The Geriatric
Assessment Tool (GAT), Quick Mild Cognitive Impairment (Qmci) Screen and Doxycycline and
Rifampicin for Alzheimer’s Disease (DARAD) trial databases; it includes the number of controls,
those with mild cognitive impairment (MCI) and specific dementia subtypes: Alzheimer’s disease
(AD), vascular dementia (VaD), mixed dementia, frontotemporal dementia (FTD), Parkinson’s disease
dementia (PDD) and Lewy body dementia (LBD) subtypes.
3. Results
In all, 3020 patients were available for analysis. A further 875 normal controls were included.
The majority of par cipants had dementia (n = 2160) of which AD was the most common subtype
(n = 1483), followed by mixed (AD-VaD) (n = 400) and VaD (n = 130). The median age of patients
presenting with cognitive symptoms (MCI/dementia) was 77 years, interquart le r nge (IQR) ±9
compared to a median age of 69 (±14) years for normal controls, p < 0.001. In al , 51% of patients
were male compared to 43% of controls, p < 0.001. Patients had completed a median of 12 (±5)
ye rs in education, similar to c ntrols (13 ± 4), albeit statistica ly significantly lower, p < 0.001.
The median SMMSE scores were 2 /30 (±8) for dementia, 28/30 (±4) for MCI and 29/30 (±2) for controls.
Median Qmci cre n scores were 38/100 (±26) for dementia, 56/100 (±20) for MCI and 74/100 (±15) for
controls. Differences in gender were seen b tw en diagnosis with the perce tage of males ranging f m
as high as 73% in those ith VaD to as low as 41% in those with dementia and como bid depression.
Characteristics of partic pants including patients and c ntrols are presented in Table 1.
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Table 1. Characteristics of participants from the Quick Mild Cognitive Impairment (Qmci) Screen validation, Doxycycline And Rifampicin for Alzheimer’s Disease
study and Geriatric Assessment Tool databases, divided according to diagnosis: Depression, controls, mild cognitive impairment (MCI) and dementia including
their Standardised Mini-Mental State Examination (SMMSE) and Qmci screen scores; comparison of SMMSE and Qmci screen score accuracy in differentiating each
diagnosis from controls.
Diagnosis N = X Age (Median &IQR)
Education






NC v CI (95%
Confidence
Intervals)





Total (All including co-morbid








co-morbid depression) 1879 78 (82 − 74 = 8) 11 (14 − 9 = 5) 971/1864 * (52%) 23 (26 − 18 = 8) 37 (49 − 24 = 25) 0.92 (0.91–0.93) 0.96 (0.95–0.97)
z = −8.3
p < 0.001
AD 1483 78 (83 − 74 = 9) 12 (14 − 9 = 5) 651/1475 * (44%) 23 (25.5 − 18 = 7.5) 37 (48 − 23 = 25) 0.94 (0.93–0.95) 0.97 (0.96–0.97) z = −5.9p < 0.001
VaD 130 74 (79 − 69 = 10) 12 (14 − 10 = 4) 95 (73%) 27 (29 − 25 = 4) 53 (64 − 40 = 24) 0.74 (0.68–0.79) 0.87 (0.84–0.91) z = −6.3p < 0.001
Mixed (AD/VaD) 400 77 (81 − 74 = 7) 11 (13 − 9 = 4) 256/393 * (65%) 22 (27 − 19 = 8) 36 (51 − 23 = 28) 0.91 (0.89–0.93) 0.95 (0.94–0.96) z = −5.7p < 0.001
AD, VaD and Mixed 2013 78 (82 − 74 = 4) 12 (14 − 9 = 5) 1002/1998 * (50%) 23 (26 − 18 = 8) 38 (50 − 24 = 26) 0.92 (0.91–0.93) 0.96 (0.95–0.97) z = 8.4p < 0.001
FTD 41 69 (71 − 62 = 9) 12 (14 − 10 = 4) 25/41 (61%) 23 (27 − 19 = 8) 42 (52 − 28 = 24) 0.90 (0.85–0.96) 0.96 (0.94–0.98) z = −2.5p = 0.01
PDD 41 75 (77 − 71 = 6) 12 (12 − 9.5 = 2.5) 28/41 (68%) 26 (29 − 21 = 8) 46 (61 − 32 = 29) 0.81 (0.72–0.90) 0.92 (0.88–0.95) z = −3.1p = 0.002
LBD 65 78 (82 − 73 = 9) 10 (14 − 8 = 6) 32/65 (49%) 24 (27 − 18 = 9) 37 (54 − 24 = 30) 0.94 (0.92–0.97) 0.94 (0.91–0.97) z = 0.11p = 0.91
MCI 860 75 (80 − 70 = 10) 12 (14 − 10 = 4) 450/852 * (53%) 28 (29 − 25 = 4) 56 (66 − 46 = 20) 0.73 (0.71–0.75) 0.85 (0.83–0.87) z = −10.8p < 0.001
Co-morbid depression 281 75 (81 − 70 = 11) 12 (14 − 10 = 4) 116/281 (41%) 25 (27 − 21 = 6) 44 (56 − 30 = 26) 0.88 (0.86–0.91) 0.93 (0.91–0.95) z = −4.2p < 0.001
MCI with co-morbid depression 94 73 (75 − 68 = 7) 12 (14 − 9 = 5) 50/92 * (54%) 26 (29 − 23 = 6) 52 (62 − 40 = 22) 0.79 (0.73–0.85) 0.90 (0.86–0.93) z = −4.4p < 0.001
MCI without co-morbid
depression 766 76 (80 − 70 = 10) 12 (14 − 10 = 4) 400/760 * (53%) 28 (29 − 26 = 3) 57 (66 − 46 = 20) 0.72 (0.70–0.75) 0.84 (0.82–0.86)
z = −10.4
p < 0.001
Controls 875 70 (76 − 62 = 14) 13 (16 − 12 = 4) 372/875 (43%) 29 (30 − 28 = 2) 74 (81 − 66 = 15) NA NA NA
AUC = area under the curve, AD = Alzheimer’s disease, CI = cognitive impairment, FTD = frontotemporal dementia, IQR = interquartile range, LBD = Lewy body dementia,
PDD = Parkinson’s dementia, VaD = vascular dementia; NA = Not applicable; * Missing data.
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Both instruments accurately differentiated cognitive impairment (MCI or dementia) from normal,
although the Qmci screen was statistically more accurate than the SMMSE (AUC of 0.93 versus 0.87,
respectively, p < 0.001). The SMMSE, at a cut-off of <24/30, had a sensitivity of 42%, specificity of 99%
with a positive predictive value of 99% and negative predictive value of 33%. The Qmci screen had a
sensitivity of 83% and specificity of 87% with a positive predictive value of 96% and negative predictive
value of 60% at its published optimal cut-off score (<62/100). Using Youden’s Index, the optimal
cut-off scores for the SMMSE was 28/30, which gave a sensitivity of 75% and specificity of 88%.
The optimal cut-off for the Qmci screen was <62. The SMMSE most accurately differentiated AD
(AUC 0.94, 95% CI: 0.93–0.95) and LBD (AUC 0.94, 95% CI: 0.92–0.97) and least accurately identified
MCI (AUC 0.73, 95% CI: 0.71–0.75), VaD (AUC 0.74, 95% CI: 0.68–0.79) and PDD (AUC 0.81, 95% CI:
0.72–0.90). The Qmci screen had statistically greater accuracy in distinguishing all dementia subtypes
except LBD (p = 0.91). The Qmci screen was more accurate than the SMMSE in separating PDD and
FTD from controls, albeit sample sizes were small. As expected, the Qmci screen had the greatest
diagnostic accuracy for identifying MCI (AUC 0.85, 95% CI: 0.83-0.87) from normal controls, which was
statistically significantly greater than the SMMSE (AUC 0.73, 95% CI: 0.71–0.75), p < 0.001. ROC curves
demonstrating the accuracy of both instruments in each type of dementia, in MCI and in those with
and without depression are presented in Figure 2a–l.
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Figure 2. Receiver operating characteristic curves (a–l) comparing the accuracy of the Quick Mild 
Cognitive Impairment (Qmci) Screen and the Standardised Mini-Mental State Examination in 
differentiating normal controls (n = 875) from those with mild cognitive impairment (MCI), different 
dementia subtypes and comorbid depression for participants included within the Qmci screen 
validation, Doxycycline And Rifampicin for Alzheimer’s Disease study and Geriatric Assessment 
Tool databases. (a). All patients (n = 3020); (b). All patients with dementia (n = 2160); (c). Dementia 
excluding depression (n = 1879); (d). Alzheimer’s dementia (n = 1483); (e). Vascular dementia (n = 130); 
(f). Mixed dementia (n = 400); (g). Alzheimer’s, vascular, mixed dementia (n = 2013); (h). 
Frontotemporal dementia (n = 41) (i). Parkinson’s disease dementia (n = 41); (j). Lewy body dementia 
(n = 65); (k). All MCI (n = 860); (l) MCI excluding depression (n = 766). 
The median subtest scores and AUC scores derived from ROC curves according to diagnosis are 
presented in Tables 2 and 3, respectively. 
 
Figure 2. Receiver operating characteristic curves (a–l) comparing the accuracy of the Quick
Mild Cognitive Impairment (Qmci) Screen and the Standardised Mini-Mental State Examination
in differentiating normal controls (n = 875) from those with mild cognitive impairment (MCI),
different dementia subtypes and comorbid depression for participants included within the Qmci screen
validation, Doxycycline And Rifampicin for Alzheimer’s Disease study and Geriatric Assessment Tool
databases. (a). All patients (n = 3020); (b). All patients with dementia (n = 2160); (c). Dementia excluding
depression (n = 1879); (d). Alzheimer’s dementia (n = 1483); (e). Vascular dementia (n = 130);
(f). Mixed dementia (n = 400); (g). Alzheimer’s, vascular, mixed dementia (n = 2013); (h). Frontotemporal
dementia (n = 41) (i). Parkinson’s disease dementia (n = 41); (j). Lewy body dementia (n = 65);
(k). All MCI (n = 860); (l) MCI excluding depression (n = 766).
The median subtest scores and AUC scores derived from ROC curves according to diagnosis are
presented in Tables 2 and 3, respectively.
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Table 2. Median scores for the Quick Mild Cognitive Impairment (Qmci) Screen subtests divided according to diagnosis: Depression, mild cognitive impairment (MCI)
and dementia.






















Total (All) 3020 8 (10 − 6 = 4) 5 (5 − 4 = 1) 12 (14 − 5 = 9) 4 (12 − 0 = 12) 5 (7 − 3 = 4) 8 (12 − 4 = 8) 43 (56 − 29 = 27)
Dementia (All including
co-morbid depression) 2160 7 (9 − 5 = 4) 5 (5 − 3 = 2) 11 (14 − 3 = 11) 4 (8 − 0 = 8) 5 (7 − 3 = 4) 8 (12 − 4 = 8) 38 (50 − 24 = 26)
Dementia (All excluding
co-morbid depression) 1879 7 (9 − 5 = 4) 5 (5 − 3 = 2) 11 (13 − 3 = 10) 0 (8 − 0 = 8) 4 (6 − 3 = 3) 8 (12 − 4 = 8) 37 (49 − 24 = 25)
AD 1483 7 (9 − 5 = 4) 5 (5 − 3 = 2) 11 (13 − 3 = 10) 0 (8 − 0 = 8) 4 (6 − 3 = 3) 8 (12 − 4 = 8) 37 (48 − 23 = 25)
VaD 130 9 (10 − 7 = 3) 5 (5 − 4 = 1) 14 (15 − 11 = 4) 8 (12 − 0 = 12) 7 (9 − 4 = 5) 10 (14 − 8 = 6) 53 (64 − 40 = 24)
Mixed (AD/VaD) 400 7 (10 − 5 = 5) 5 (5 − 3 = 2) 10 (14 − 2 = 12) 0 (8 − 0 = 8) 5 (7 − 3 = 4) 8 (12 − 4 = 8) 35.5 (51 − 23 = 28)
AD, VaD and Mixed 2013 7 (9 − 5 = 4) 5 (5 − 3 = 2) 11 (14 − 3 = 11) 0 (8 − 0 = 8) 5 (7 − 3 = 4) 8 (12 − 4 = 8) 38 (50 − 24 = 26)
FTD 41 9 (10 − 6 = 4) 5 (5 − 3 = 2) 12 (13 − 5 = 8) 4 (8 − 0 = 8) 4 (7 − 3 = 4) 8 (12 − 4 = 8) 43 (55 − 30 = 25)
PDD 41 9.5 (10 − 7 = 3) 5 (5 − 4 = 1) 12.5 (15 − 7 = 8) 8 (12 − 0 = 12) 5.5 (7 − 4 = 3) 10 (14 − 8 = 6) 46 (61 − 32 = 29)
LBD 65 8 (10 − 6 = 4) 5 (5 − 3 = 2) 7 (12 − 1 = 11) 8 (12 − 0 = 12) 4 (6 − 3 = 3) 8 (10 − 4 = 6) 37 (54 − 24 = 30)
MCI 860 10 (10 − 8 = 2) 5 (5 − 5 = 0) 14 (15 − 12 = 3) 12 (16 − 4 = 12) 7 (9 − 5 = 4) 12 (16 − 8 = 8) 56 (66 − 46 = 20)
Co-morbid depression 281 8 (10 − 6 = 4) 5 (5 − 4 = 1) 11 (14 − 4 = 10) 4 (12 − 0 = 12) 6 (8 − 3 = 5) 10 (14 − 4 = 10) 44 (56 − 30 = 26)
MCI with co-morbid
depression 94 9 (10 − 7 = 3) 5 (5 − 4 = 1) 13 (15 − 10 = 5) 8 (12 − 4 = 8) 8 (8 − 4 = 4) 12 (14 − 8 = 6) 51.5 (62 − 40 = 22)
MCI without co-morbid
depression 766 10 (10 − 8 = 2) 5 (5 − 5 = 0) 14 (15 − 12 = 3) 12 (16 − 4 = 12) 7 (9 − 5 = 4) 12 (16 − 8 = 8) 57 (66 − 46 = 20)
Controls 875 10 (10 − 10 = 0) 5 (5 − 5 = 0) 15 (15 − 14 = 1) 16 (20 − 12 = 8) 10 (13 − 8 = 5) 18 (22 − 14 = 8) 74 (81 − 66 = 15)
AD = Alzheimer’s disease, FTD = frontotemporal dementia, LBD = Lewy body dementia, PDD = Parkinson’s dementia, VaD = vascular dementia (IQR = interquartile range).
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Table 3. Comparison of the accuracy of the Quick Mild Cognitive Impairment (Qmci) Screen subtests in differentiating each diagnosis from controls (n = 875):
Depression, mild cognitive impairment (MCI) and dementia.














Total (All) 3020 0.81 (0.79–0.82) 0.62 (0.60–0.64) 0.80 (0.79–0.82) 0.86 (0.85–0.87) 0.85 (0.84–0.87) 0.87 (0.85–0.88) 0.93 (0.92–0.94)
Dementia (All including
co-morbid depression) 2160 0.86 (0.85–0.87) 0.65 (0.63–0.67) 0.85 (0.83–0.86) 0.90 (0.89–0.91) 0.89 (0.88–0.90) 0.89 (0.88–0.91) 0.96 (0.95–0.96)
Dementia (All excluding
co-morbid depression) 1879 0.87 (0.85–0.88) 0.66 (0.64–0.68) 0.85 (0.84–0.87) 0.90 (0.89–0.92) 0.90 (0.88–0.91) 0.90 (0.89–0.91) 0.96 (0.95–0.97)
AD 1483 0.88 (0.87–0.90) 0.66 (0.64–0.68) 0.85 (0.84–0.87) 0.91 (0.90–0.93) 0.91 (0.89–0.92) 0.91 (0.89–0.92) 0.97 (0.96–0.97)
VaD 130 0.71 (0.66–0.77) 0.56 (0.50–0.61) 0.72 (0.67–0.77) 0.80 (0.75–0.84) 0.80 (0.77–0.84) 0.81 (0.77–0.85) 0.87 (0.84–0.91)
Mixed (AD/VaD) 400 0.84 (0.82–0.87) 0.65 (0.61–0.68) 0.85 (0.82–0.87) 0.90 (0.88–0.92) 0.89 (0.87–0.91) 0.89 (0.87–0.91) 0.95 (0.94–0.96)
AD, VaD & Mixed 2013 0.86 (0.85–0.88) 0.65 (0.63–0.67) 0.84 (0.83–0.86) 0.90 (0.89–0.91) 0.90 (0.88–0.91) 0.90 (0.88–0.91) 0.96 (0.95–0.97)
FTD 41 0.78 (0.69–0.87) 0.63 (0.53–0.73) 0.88 (0.81–0.94) 0.90 (0.87–0.95) 0.85 (0.78–0.92) 0.88 (0.83–0.93) 0.96 (0.94–0.98)
PDD 41 0.71 (0.61–0.81) 0.68 (0.58–0.77) 0.73 (0.63–0.82) 0.84 (0.77–0.91) 0.85 (0.79–0.91) 0.83 (0.77–0.88) 0.92 (0.88–0.95)
LBD 65 0.82 (0.74–0.88) 0.66 (0.58–0.74) 0.92 (0.87–0.96) 0.84 (0.79–0.90) 0.89 (0.85–0.93) 0.86 (0.81–0.92) 0.94 (0.91–0.97)
MCI 860 0.68 (0.65–0.70) 0.54 (0.51–0.57) 0.69 (0.67–0.72) 0.76 (0.74–0.78) 0.76 (0.74–0.78) 0.80 (0.77–0.81) 0.85 (0.83–0.87)
Co-morbid depression 281 0.80 (0.77–0.84) 0.62 (0.57–0.66) 0.81 (0.78–0.84) 0.86 (0.84–0.89) 0.84 (0.82–0.87) 0.84 (0.82–0.87) 0.93 (0.91–0.95)
MCI with co-morbid
depression 94 0.75 (0.69–0.82) 0.59 (0.52–0.65) 0.75 (0.70–0.81) 0.82 (0.78–0.87) 0.80 (0.76–0.85) 0.80 (0.75–0.84) 0.90 (0.86–0.93)
MCI without co-morbid
depression 766 0.67 (0.64–0.69) 0.53 (0.50–0.56) 0.69 (0.66–0.71) 0.75 (0.73–0.77) 0.76 (0.73–0.78) 0.80 (0.76–0.81) 0.84 (0.82–0.86)
AD = Alzheimer’s disease, FTD = frontotemporal dementia, LBD = Lewy body dementia, PDD = Parkinson’s dementia, VaD = vascular dementia; AUC = area under the curve;
CI = confidence intervals.
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ROC curves comparing the subtests of the Qmci screen are presented in Figure 3a–l. The highest
median score for the clock drawing subtest was found in those with VaD (14/15), the lowest was in LBD
(7/15). The logical memory subtest was the most accurate of the Qmci screen subtests for most dementia
subtypes and MCI (AUC 0.80, 95% CI: 0.77–0.81). Orientation was accurate for AD (AUC 0.88, 95%
CI:) but had particularly low accuracy in VaD (AUC 0.71, 95% CI: 0.66–0.71), FTD (AUC 0.78, 95% CI:
0.69–0.87), PDD (AUC 0.71, 95% CI: 0.61–0.81) and MCI (AUC 0.68, 95% CI: 0.65–0.70). Clock drawing
had the highest accuracy for identifying PDD (AUC 0.92, 95% CI: 0.87–0.96). Word registration had the
lowest accuracy for all dementia subtypes and MCI.
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Those diagnosed with dementia and co-morbid depression were younger (z = −5.9, p < 0.001)
and more likely to be female (X2 = 11.4, p < 0.001) than those without comorbid depression.
There was no statistically significant difference in the number of years in education (z = −1.3,
p = 0.21). Those diagnosed with dementia (all subtypes excluding MCI) with co-morbid depression
(n = 281) had statistically significantly higher median Qmci screen and SMMSE scores than those
without (n = 1879) depression: Median Qmci screen scores of 44 versus 37, respectively (z = −4.771,
p < 0.001) and median SMMSE scores of 25 versus 23, respectively (z = −5.627, p < 0.001). Contrasting
this, comparison of median scores for MCI with and without depression showed that scores were
significantly lower for those with co-morbid depression for both the Qmci screen, (52 and 57 respectively,
z = −2.927, p = 0.003) and SMMSE (26 and 28 respectively, z = −3.302, p = 0.001). Co-morbid depression
lowered the diagnostic accuracy of both instruments for dementia but improved the accuracy in
those with MCI. All Qmci screen subtest scores were less accurate for MCI among those patients with
co-morbid depression.
4. Discussion
This study compares the diagnostic accuracy of the SMMSE and Qmci screen in different dementia
subtypes using a large sample of patients pooled from three different datasets using AUC values
as a global measure of diagnostic accuracy. The results show that the SMMSE and Qmci screen are
both accurate CSIs when used to identify dementia in patients presenting with cognitive symptoms
to geriatric and memory clinics compared with normal controls. Overall, the Qmci screen had high
sensitivity and specificity in separating normal controls from those with cognitive impairment (MCI
or dementia with or with co-morbid depression). The SMMSE had poor sensitivity, albeit excellent
specificity at its widely-used cut-off. These results would be expected as the Qmci screen contains
more challenging tests of episodic memory [28], which are better able to differentiate MCI from mild
dementia [8,29]. The SMMSE is overly weighted towards tests of orientation (one-third of its points),
which is best able to identify established dementia [28]. Further, while a cut-off of <24/30 is widely
applied for the SMMSE, recent studies suggest that higher cut-offs between 26 [37] and 29 [13], closer to
that found here, are more accurate and produce a better balance between sensitivity and specificity.
As with its’ original validation study [8,28], this analysis confirms the Qmci screen is more accurate
overall and that its logical memory subtest is its most accurate for separating MCI from normal controls.
It also had high levels of accuracy for most dementia subtypes and patients with and without co-morbid
depression. The SMMSE, while it had good to excellent accuracy in differentiating most dementia
subtypes from normal controls, was less accurate in identifying MCI [8], and had only fair accuracy
in identifying VaD (AUC of 0.74) from controls, supporting previous studies in these conditions,
where an alternative instrument is suggested [17]. Similarly, while the SMMSE’s accuracy in detecting
PDD from normal controls was good (AUC 0.81), it performed relatively poorly compared to the
Qmci screen, supporting evidence that it is less suitable due to both floor and ceiling effects in those
with movement disorders [18,38]. The study also examined the subtests of the Qmci screen and their
differential accuracy in separating those with MCI and dementia from normal controls. As was found
in the initial validation, logical memory was most accurate in identifying MCI [28]. Clock drawing was
most accurate in detecting LBD but the accuracy for PDD was relatively lower. Clock drawing is often
grossly abnormal in LBD, particularly for copying rather than drawing clocks [39]. Differences between
LBD and PDD were unexpected and it is likely that small numbers influenced the results. Orientation
was only accurate for AD and mixed dementia having poor accuracy for other dementia subtypes
and MCI.
In this study, co-morbid depression had a significant impact on CSI scores; those with dementia
and depression scored significantly higher on both the SMMSE and Qmci screen than those without.
This was unexpected as other studies [22] suggest that impaired attention and other cognitive deficits
associated with low mood negatively impact on scores. Nevertheless, co-morbid depression did
lower the diagnostic accuracy of both instruments for differentiating dementia from normal controls.
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The opposite effect was seen for MCI; those with co-morbid depression scored less well on both CSIs,
which had higher diagnostic accuracy for these patients. This suggests that comorbid depression
may influence CSIs in different ways depending on the diagnostic stage of cognitive impairment.
Depression may also have a greater clinical effect at earlier stages of disease progression with evidence
that depressive symptoms increase the risk for converting from MCI to dementia, particularly amnestic
type to AD [21,40].
The strength of this study is derived from its large sample size and careful pooling of data derived
from similar data sets collected by the same principal investigator. This study also has limitations.
Pooling data from discrete, albeit related, datasets with different populations may have created bias.
Some data on gender were missing and subtest data for the SMMSE were not available across all
three datasets, which limited the analysis. The number of patients with atypical or less common
dementia subtypes was small and may be unrepresentative of the true performance of the instruments
in that subtype, leading to bias. The data collection began in 1999 when the awareness of LBD was
low, potentially resulting in misclassification bias. Likewise, only patients with AD or those with AD,
VaD and mixed dementia were included in the DARAD and the Qmci validation databases respectively.
In addition, the prevalence of cognitive impairment (MCI/dementia) was high among those attending
these geriatric and memory clinics potentially leading to spectrum bias. Further, this study was a
retrospective review of patients with no detailed information available regarding the type of depressive
symptoms. Similarly, it was not possible to assess MCI subtypes in this study, though the majority of
patients in the GAT database reported amnestic type symptoms, suggesting that most had aMCI. Finally,
the statistical analysis was limited to using AUC scores as a global measure of diagnostic accuracy
and further research is now planned to explore the psychometric properties of these instruments in
different dementia subtypes and to identify the optimal cut-off scores.
In summary, this study reaffirms that both the SMMSE and Qmci screen are useful in separating
patients with dementia from normal controls. It confirms the superior accuracy of the Qmci screen
in MCI. It also shows that different short screens have significantly different accuracy in different
dementia subtypes, suggesting that pre-screen/pre-test suspicion of a possible diagnosis (MCI or
specific dementia subtype) based upon history and examination should direct the choice of instrument
to be used when performing cognitive screening. This is important as time is limited in clinical
practice and short CSIs can only include a limited number of domains, resulting in a time-accuracy
trade-off supporting the need for careful selection a priori [41]. The results also suggest that a history
of depression may affect the accuracy of cognitive screens, particularly in those with MCI in which
it lowers median scores but increased the diagnostic accuracy of CSIs. The opposite effect was seen
in dementia. This shows the importance of asking about depression when undertaking cognitive
screening [20] and that the effect of comorbid depression on cognitive screening scores merits further
investigation. Understanding the optimal cut-offs for these instruments and other short CSIs is also
important, so that not only the most appropriate instrument is used in the right setting but also the
correct cut-off score is applied. To date, no condition-specific cut-off scores for the SMMSE or Qmci
screen are available, highlighting that this is an area requiring more research. Further study is also
required to confirm these findings and compare with sensitive and specific instruments such as the
MoCA and the Mini-Addenbrooke’s Cognitive Examination [42].
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